Special Issue

Functional Products Used in Alleviation of Oxidative Stress Diseases and Interaction with Human Microbiota 2.0

Message from the Guest Editor

Functional products (such as probiotics, prebiotics, dietary fibers, plant extracts, etc.) are useful tools in reducing or alleviating the pathological effects of oxidative stress. Moreover, postbiotics and parapostbiotics have emerged as new products for modulating microbiota bioactivity. The development of innovative products is a significant research area that is providing evidence for disease control and the prevention of degenerative pathologies. Thus, for this Special Issue, we aim to publish recent studies presenting possible in vitro and in vivo evidence of a modulation response through the microbiota pattern. You are also invited to contribute research based on the effect of different drugs that are used in degenerative pathologies and possible interactions with the human microbiota. Side effects are significant in disease management and interactions with associated pathologies. We would like to encourage you to send papers on these and other related aspects relevant to the issue.

- microbiota modulation
- pathology–microbiota
- immunomodulatory effects
- polyphenols
- pro-, pre-, synbiotic nutraceuticals
- postbiotics

Guest Editor

Prof. Dr. Emanuel Vamanu
Faculty of Biotechnology, University of Agricultural Sciences and Veterinary Medicine, 011464 Bucharest, Romania

Deadline for manuscript submissions

closed (30 June 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/133053

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).